Evidence map›Paper›PMID 36516194›Full record

ArticlePloS one2022

Establishment of preanalytical conditions for microRNA profile analysis of clinical plasma samples.

Kuno Suzuki, Tatsuya Yamaguchi, Masakazu Kohda, Masami Tanaka, Hiroyuki Takemura, Mitsuru Wakita, Yoko Tabe, Shunsuke Kato, Motomi Nasu, Takashi Hashimoto and 28 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors at 5 institutions in 1 country.

Kuno SuzukiHealthcare Business Department, PFDeNA, Inc., Tokyo, Japan.ORCID 0000-0001-9776-9008
Tatsuya YamaguchiHealthcare Business Department, PFDeNA, Inc., Tokyo, Japan.
Masakazu KohdaHealthcare Business Department, PFDeNA, Inc., Tokyo, Japan.
Masami TanakaHealthcare Business Department, PFDeNA, Inc., Tokyo, Japan.
Hiroyuki TakemuraDepartment of Clinical Laboratory, Juntendo University Hospital, Tokyo, Japan.
Mitsuru WakitaDepartment of Clinical Laboratory, Juntendo University Hospital, Tokyo, Japan.
Yoko TabeDepartment of Clinical Laboratory, Juntendo University Hospital, Tokyo, Japan.
Shunsuke KatoDepartment of Clinical Oncology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Motomi NasuDepartment of Esophageal and Gastroenterological Surgery, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Takashi HashimotoDepartment of Esophageal and Gastroenterological Surgery, Juntendo University Graduate School of Medicine, Tokyo, Japan.ORCID 0000-0001-8967-3815
Shinji MineDepartment of Esophageal and Gastroenterological Surgery, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Nobuko SerizawaDepartment of Gastroenterology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Ko TomishimaDepartment of Gastroenterology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Akihito NagaharaDepartment of Gastroenterology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Takahisa MatsudaCancer Screening Center, National Cancer Center Hospital, Tokyo, Japan.
Taiki YamajiDivision of Epidemiology, National Cancer Center Institute for Cancer Control, Tokyo, Japan.
Shoichiro TsuganeDivision of Cohort Research, National Cancer Center Institute for Cancer Control, Tokyo, Japan.
Yutaka SaitoDepartment of Endoscopy, National Cancer Center Hospital, Tokyo, Japan.
Hiroyuki DaikoDepartment of Esophageal Surgery, National Cancer Center Hospital, Tokyo, Japan.
Takaki YoshikawaDepartment of Gastric Surgery, National Cancer Center Hospital, Tokyo, Japan.
Ken KatoDepartment of Head and Neck, Esophageal Medical Oncology / Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.ORCID 0000-0002-1733-5072
Takuji OkusakaDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Takahiro OchiyaLaboratory of Integrative Oncology, National Cancer Center Research Institute, Tokyo, Japan.
Yusuke YamamotoLaboratory of Integrative Oncology, National Cancer Center Research Institute, Tokyo, Japan.
Shoji YotsuiClinical Laboratory, Osaka International Cancer Institute, Osaka, Japan.
Takashi YamamotoClinical Laboratory, Osaka International Cancer Institute, Osaka, Japan.
Tomoyuki YamasakiClinical Laboratory, Osaka International Cancer Institute, Osaka, Japan.
Hiroshi MiyataDepartment of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.
Masayoshi YasuiDepartment of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.
Takeshi OmoriDepartment of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.
Kazuyoshi OhkawaDepartment of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka, Japan.
Kenji IkezawaDepartment of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka, Japan.
Tasuku NakaboriDepartment of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka, Japan.
Naotoshi SugimotoDepartment of Medical Oncology, Osaka International Cancer Institute, Osaka, Japan.
Toshihiro KudoDepartment of Medical Oncology, Osaka International Cancer Institute, Osaka, Japan.
Keiichi YoshidaNext-generation Precision Medicine Research Center, Osaka International Cancer Institute, Osaka, Japan.
Masayuki OhueNext-generation Precision Medicine Research Center, Osaka International Cancer Institute, Osaka, Japan.
Takashi NishizawaHealthcare Business Department, PFDeNA, Inc., Tokyo, Japan.
Osaka International Cancer Institute · JPJuntendo University · JPJuntendo University Hospital · JPNational Cancer Center Hospital East · JPTokyo National Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The relationship between the expression of microRNAs (miRNAs) in blood and a variety of diseases has been investigated. MiRNA-based liquid biopsy has attracted much attention, and cancer-specific miRNAs have been reported. However, the results of analyses of the expression of these miRNAs vary among studies. The reproduction of results regarding miRNA expression levels could be difficult if there are differences in the data acquisition process. Previous studies have shown that the anticoagulant type used during plasma preparation and sample storage conditions could contribute to differences in measured miRNA levels. Thus, the impact of these preanalytical conditions on comprehensive miRNA expression profiles was examined. First, the miRNA expression profiles of samples obtained from healthy volunteers were analyzed using next-generation sequencing. Based on an analysis of the library concentration, human genome identification rate, ratio of unique sequences and expression profiles, the optimal preanalytical conditions for obtaining highly reproducible miRNA expression profiles were established. The optimal preanalytical conditions were as follows: ethylenediaminetetraacetic acid (EDTA) as the anticoagulant, whole-blood storage at room temperature within 6 hours, and plasma storage at 4°C or -20°C within 30 days. Next, plasma samples were collected from 60 cancer patients (3 facilities × 20 patients/facility), and miRNA expression profiles were analyzed. There were no significant differences in measurements except in the expression of erythrocyte-derived hsa-miR-451a. However, the variation in hsa-miR-451a levels was smaller among facilities than among individuals. This finding suggests that samples obtained from the same facility could show significantly different degrees of hemolysis across individuals. We found that the standardization of anticoagulant use and storage conditions contributed to reducing the variation in sample quality across facilities. The findings from this study could be useful in developing protocols for collecting samples from multiple facilities for cancer screening tests.

Indexed as

MicroRNAsAnticoagulantsGene Expression ProfilingHealthy VolunteersHigh-Throughput Nucleotide SequencingHumansPlasmaAnticoagulantsMicroRNAs

Identifiers

PMID36516194
PMCPMC9750036
OpenAlexW4311472163

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.